ZIVO Bioscience: Coccidiosis Treatment Licensing Opportunities

ZIVO Bioscience, Inc. (OTCQB: ZIVO) has made significant strides in its mission to develop and commercialize a novel, non-antibiotic treatment for coccidiosis in broiler chickens. The company's recent announcements highlight its progress in licensing opportunities, regulatory clarity, and potential market impact.

ZIVO's innovative product candidate, derived from proprietary algal cultures, has demonstrated remarkable efficacy in real-world conditions. The company's 42-day validation study, conducted in collaboration with the University of Delaware, confirmed the product's ability to maintain broiler health against coccidiosis, outperforming market-leading products and offering a non-antibiotic, non-chemical alternative. These results have positioned ZIVO to pursue strategic partnerships with global animal health companies.

In a recent development, ZIVO received a letter from the U.S. Department of Agriculture's (USDA) Center for Veterinary Biologics (CVB) affirming that the agency has claimed jurisdiction for reviewing the company's novel immune-modulating biologic. This regulatory clarity enables ZIVO to advance discussions with the CVB on the final product development plan, regulatory strategy, and data requirements for licensure. The CVB's jurisdictional announcement removes regulatory ambiguity and provides a path for a comprehensive review, expediting ZIVO's approval path.



ZIVO's product candidate represents a substantial market opportunity, given the global poultry industry's annual spend of over $1.5 billion on coccidiosis control. Assuming a conservative royalty rate of 5% on annual sales of $500 million, ZIVO could potentially earn $25 million in royalties annually, contributing significantly to its overall revenue growth.

The company's strategic focus on licensing opportunities, regulatory clarity, and market potential positions ZIVO Bioscience as an attractive investment prospect in the animal health sector. As the company continues to advance its product pipeline and expand its market reach, investors should closely monitor ZIVO's progress and consider the potential long-term value of its innovative coccidiosis treatment.